Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.54
- Piotroski Score 1.00
- Grade Buy
- Symbol (ZVRA)
- Company Zevra Therapeutics, Inc.
- Price $6.85
- Changes Percentage (-1.3%)
- Change -$0.09
- Day Low $6.61
- Day High $6.95
- Year High $8.95
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $21.00
- High Stock Price Target $25.00
- Low Stock Price Target $17.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.32
- Trailing P/E Ratio -3.52
- Forward P/E Ratio -3.52
- P/E Growth -3.52
- Net Income $-46,049,000
Income Statement
Quarterly
Annual
Latest News of ZVRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ZVRA Stock Price | Zevra Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Zevra Therapeutics, Inc. is a specialty pharmaceutical company focused on developing prodrugs for medical conditions like ADHD and pain. Founded in 2006, it utilizes Ligand Activated Therapy to target...
By MarketWatch | 1 month ago -
Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
Zevra Therapeutics, Inc. is nearing breakeven, with analysts predicting profitability by 2026. The company's growth rate is estimated at 65% annually, but its high debt level poses a risk....
By Yahoo! Finance | 3 months ago